The people in our network are world leading experts in their fields related to pain and pain therapy.
As a result of our publication in JPET with University of Bristol, contact was established with Prof. Amynah Pradhan at the University of Illinois, Chicago.Read more →
New CEO appointed
The board of PharmNovo AB is pleased to announce that former VP Business Development Per von Mentzer assumed the position as new Chief Executive Officer of PharmNovo AB effective May 2020.Read more →
JPET approves PN6047
In collaboration with our research partners at the University of Bristol, we have had a manuscript detailing the results of our preclinical studies of PN6047 accepted for publication in the highly cited Journal of Experimental Pharmacology and Therapeutics (JPET), the official journal of the American Society for Pharmacology and Experimental Therapeutics (ASPET).Read more →
Moving into The Spark
In September PharmNovo AB officially moved to Medicon Village in Lund and the newly opened building ”The Spark”. Being located at Medicon Village offers great opportunities for networking and finding new collaboration and service partners. Being one of the largest life science hubs in the Nordics, Medicon is also a fantastic platform for marketing our company and attracting future investors and partners.Read more →
the Material on this website as well as all other material used in presentations or printed matters that have been prepared by PharmNovo AB, are general background information about PharmNovo’s activities as at the date of the publication or presentation. The information is given in summary form and does not purport to be complete. All information, including forecast financial information, should not be considered as advice or a recommendation to investors or potential investors in relation to → holding, purchasing or selling securities or other financial products or instruments and does not take into account your particular investment objectives, financial situation or needs. Before acting on any information you should consider the appropriateness of the information having regard to these matters, any relevant offer document and in particular, you should seek independent financial advice.
All securities and financial product or instrument transactions involve risks, which include (among others) the risk of adverse, financial or political developments and other risks. material on this website or in presentations may contain forward looking statements including statements regarding our intent, belief or current expectations with respect to PharmNovo’s development opportunities and operations, market conditions, results of operation and financial condition, capital adequacy, specific provisions and risk management practices. Readers are cautioned not to place undue reliance on these forward looking statements.
PharmNovo does not undertake any obligation to publicly or otherwise release the result of any revisions to these forward looking statements to reflect events or circumstances after the date hereof to reflect the occurrence of unanticipated events or the development of pharmaceutical compounds providing negativa results. While due care has been used in the preparation of forecast information, actual results may vary in a materially positive or negative manner. Forecasts and hypothetical examples are subject to uncertainty and contingencies outside PharmNovo’s control. past performance and achieved development milestones are not reliable indications of future performance.